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Abstract 
Focal cancer therapy can improve clinical outcomes. Here, we evaluated injectable 
heparin-containing hydrogel material loaded with doxorubicin as a focal breast cancer 
therapy. We utilized a binary heparin/polyethylene glycol (PEG) hydrogel that was 
processed post synthesis into hydrogel microparticle aggregates to yield a readily 
injectable hydrogel. When loaded with doxorubicin, the injectable hydrogel microparticle 
aggregates had excellent short- and long-term anticancer activity against human breast 
cancer cells in vitro.  Efficacy as a focal anticancer therapy was also evaluated in vivo by 
local injection of the doxorubicin-loaded PEG-heparin hydrogel microparticle aggregates 
into mice with established human orthotopic breast tumours. Animals showed significant 
antitumour responses by reduction in both primary tumour growth and metastasis when 
compared to animals which received the equivalent doxorubicin dose via an intravenous 
bolus injection. Overall, PEG-heparin hydrogel microparticle aggregates are emerging as 
a potential anticancer drug delivery system for focal therapy. 
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Introduction 
Focal chemotherapy is routinely used for a number of malignancies. For example, bladder cancer 
is often treated with intravesicular chemotherapy, while high-grade malignant glioma is treated 
using carmustine-containing synthetic copolymer wafers (Gliadel Wafer). In the latter case, after 
tumour resection, the gliadel wafers are placed into the tumour bed, and more than 15% of the 
dose remains at the local site at 7 days post application, thereby increasing brain concentrations 
more than 113-fold when compared to systemic delivery of carmustine 
1
.  
 
The standard clinical practice for early stage breast cancer is typically surgical resection of the 
primary breast tumour, followed by localized radiotherapy to the affected breast 
2
. This treatment 
strategy reduces ipsilateral tumour recurrence and enhances overall survival 
3-4
. Therefore, 
locoregional control is necessary to improve long-term clinical outcomes. Notably, in this patient 
population, systemic chemotherapy provides limited control over the locoregional disease 
2
. The 
finding that dual therapy consisting of tumour resection and local irradiation significantly 
improves treatment success indicates that direct application of chemotherapy to the primary 
tumour site might improve current clinical outcomes 
3-4
. Furthermore, target radiotherapy applied 
to the tumour bed at the time of surgery has produced encouraging results in low risk women 
over the age of 45 (TARGIT-A trial) 
5
 and is now being tested in high risk women (TARGIT-B 
trial). However, for low risk ductal carcinoma in situ (DCIS) the current surgical intervention is 
being challenged  and thus a more conservative treatment strategy for DCIS might emerge in the 
future (Phase III LORIS clinical trial, UK Clinical Research Network ID 16736 and COMET 
study in the United States)
6
. 
 
-	 4	
Synthetic polymers are widely used for drug delivery applications; for example, poly(2-
hydroxyethyl methacrylate) (PHEMA) was used in first generation hydrogels. Since then several 
synthetic polymers, such as polyesters, polyphosphazene and poly(ethylene glycol) (PEG), have 
been developed 
7
. Many of these polymers are in pre-clinical development for controlled drug 
delivery applications, including anticancer drug delivery 
8
. Of these, PEG has an excellent 
clinical track record despite being non-biodegradable; careful selection of molecular weight, 
dose and route of administration have contributed to its clinical safety record. Based on the 
existing clinical experience with PEG, PEG-based hydrogels have been developed to deliver a 
wide spectrum of payloads including chemotherapeutic agents (e.g. doxorubicin, paclitaxel) 
9
, 
therapeutic proteins (e.g. befaziumab, exenatide) 
10-11
 and precision medicines (e.g. crizotinib) 
12
. 
Payload delivery can be achieved through polymer network degradation, drug diffusion or a 
combination of both these processes. The use of ÒbioresponsiveÓ PEG polymers ensures network 
degradation, which in turn regulates drug release and ultimately leads to polymer elimination. 
For example, PEG-based hydrogels have been developed with matrix metalloprotease (MPP)-
sensitive peptide linkers that permit stimulus-mediated carrier degradation and subsequent 
polymer elimination (reviewed by 
8
).  A number of biopolymer-based systems are also in pre-
clinical development for the focal cancer therapy. For example, we have developed silk-based 
films and self-assembling silk hydrogels for the focal delivery of chemotherapeutic drugs and 
precision medicines 
13-14
.  
 
Biopolymers for drug delivery are typically expected to elicit no biological response; however, 
many biopolymers have intrinsic biological properties. For example, heparin in its freely 
diffusible as well as conjugated form binds to the enzyme inhibitor antithrombin III to induce a 
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conformational change of the protein and ultimately inhibit the coagulation cascade 
15
. An 
association between venous thromboembolism and cancer has long been recognised; thus, 
heparin-based prophylaxis and treatment are routine clinical practices 
16
. Furthermore 
experimental 
16-17
 and clinical data 
18
 suggest that freely diffusible heparin displays an array of 
anticancer properties; therefore, heparin use in cancer patients goes beyond the prevention of 
venous thromboembolism. Furthermore, heparin is a substrate for heparanase which is 
overexpressed in tumours 
19
, and therefore might facilitate on-demand lead drug release. Clinical 
experience with heparin spans more than 80 years, including various routes of administration 
(e.g., subcutaneously or by intravenous injections). Therefore, heparin is emerging as a valuable 
building block for drug delivery systems due to its biological properties.  Heparin-containing 
hydrogels have been evaluated in tissue/disease specific niche models (e.g. 
20-21
) and as an 
advanced coagulation coating 
15
. The present study pioneers injectable heparin-containing 
hydrogels as a prospective anticancer therapy. 
 
The aim of the current study was to develop and test semi-synthetic hydrogel-based 
microparticle aggregates for focal cancer therapy. We designed microparticles using PEG-
heparin hydrogels; PEG stars (starPEG) with a molecular weight (MW) of 10,000 g/mol were 
chosen because these polymers permit the formation of hydrogels with a defined 6 +/- 3 nm 
mesh size. A bio-hybrid PEG-heparin hydrogel was fabricated to evaluate the efficacy of heparin 
hydrogel materials as drug-binding reservoirs and the advantages of local over the systemic 
delivery of doxorubicin in preventing cancer progression.   
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Experimental 
Reagents for PEG-heparin hydrogels  
Heparin (MW 14,000 g/mol) was purchased from Calbiochem (Merck, Darmstadt, Germany) 
and four-armed PEG stars (starPEG; Mn 10 × 10
3
; polydispersity index 1.09) were obtained from 
PolymerSource (Montreal, Canada). N-hydroxysulfosuccinimide (NHS) was purchased from 
Sigma-Aldrich (Munich, Germany). Doxorubicin hydrochloride salt was purchased from LC 
Laboratories (Woburn, MA, USA). All solvents and N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC hydrochloride) for hydrogel synthesis were purchased 
from IRIS Biotech GmbH (Marktredwitz, Germany). All reagents were used without further 
purification.  
 
Preparation of PEG-heparin hydrogels 
Hydrogels were prepared as previously described 
22
. Briefly, a two-fold excess of EDC-
hydrochloride and a stoichiometric amount of NHS were added to a pH 7.0 solution of 
heparin in phosphate buffered saline (PBS). The heparin-NHS ester was formed by 
maintaining the reaction mixture at 4
o
C for 15 min. Next, a stoichiometric amount of 
starPEG solution in PBS (pH 7.4) was added. The total volume of the reaction mixture was 1 
ml and the total weight of the heparin and starPEG mixture was 11 %w/w. The reagents 
underwent a solution-gel (solgel) transition in less than 1 h and was kept overnight at room 
temperature for completion of the reaction. The hydrogel was then swollen in purified water 
(Millipore, Billerica, MA, USA), followed by PBS, to remove the side products of the 
reaction. The swollen hydrogels were then stored in PBS at 4¡C until use. Hydrogels used for 
in vitro and in vivo applications were prepared under sterile conditions and reagent solutions 
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were sterilized by filtration through 0.2µm filters (polyvinylidene fluoride membrane, 
Acrodisc LC 13mm, PALL Life Science, Port Washington, NY, USA). 
 
 Preparation of PEG-heparin hydrogel microparticles 
Injectable hydrogel microparticles were prepared as previously described 
23
. Briefly, 1 ml of 
hydrogel was minced using a sterile spatula, collected in a 1 ml syringe and repeatedly 
extruded through a 0.9 mm needle (20G) until a homogenised hydrogel was obtained. The 
procedure was then repeated with a 0.45 mm needle (26G) yielding 25-50 µm particles. 
These hydrogel microparticles were washed with 1 ml purified water by vortexing, 
centrifuged at 12,110 g for 2 min at room temperature and the supernatant was aspirated. 
This washing procedure was repeated twice more with purified water followed by four PBS 
washes. As the final step, the microparticles were centrifuged at 12,110 g for 6 min and any 
released liquid was removed. The resulting hydrogel microparticle aggregates were stored at 
4
¡
C until use. Microparticle aggregates for in vitro and in vivo applications were prepared 
under sterile conditions. After centrifugation, the formed hydrogel microparticle aggregate 
was uploaded into sterile syringes and stored at 4¡C. 
 
Loading of the PEG-heparin hydrogel microparticle aggregates with doxorubicin 
A 1 ml hydrogel microparticle volume was prepared under sterile conditions, as detailed 
above. Next, 50 µl of sterile water containing doxorubicin at either 40, 200, 400 or 800 µg 
were added. Samples were extensively vortexed for 15 min and hydrogel microparticles were 
left to equilibrate at room temperature for 60 min. The mixing-equilibration procedure was 
repeated until hydrogel microparticle aggregates showed an even drug distribution. Next, the 
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hydrogel microparticle aggregates were centrifuged at 12,110 g for 15 min and the 
supernatant was removed. Doxorubicin-loaded PEG-heparin hydrogel microparticle 
aggregates were filled into 1 ml syringes, which were then hermetically sealed and stored at 
4¡C until use. 
 
In vitro doxorubicin release from PEG-heparin hydrogel microparticle aggregates 
To assess doxorubicin release from 50 µl hydrogel microparticle aggregates, samples were 
incubated with PBS at 37¡C. Cumulative drug release was monitored by removing and 
replacing the buffer at the indicated time points and measuring doxorubicin-associated UV 
absorbance at 490 nm (Beckman Coulter, DU800, USA). PEG-heparin hydrogel 
microparticle aggregates without doxorubicin were used to establish an absorbance reference 
value (data not shown). For studies that determined the binding affinity of doxorubicin to the 
PEG-heparin hydrogel microparticle aggregates drug release was monitored without changes 
of the release buffer. 
 
In vitro studies breast cancer studies 
The breast cancer cell lines MDA-MB-231 and MCF-7 were obtained from ATCC (Manassas, 
VA, USA). Cells were maintained in a humidified atmosphere of 5 % CO2 at 37 ¡C, and cultures 
were subcultured every 2Ð3 days. The MDA-MB-231 cells were grown in RPMI 1640 with 10 
%v/v FBS; MCF-7 cells were cultured in DMEM (4.5 g glucose, 110 mg sodium pyruvate) 
supplemented with 10 %v/v FBS and 10 µg/ml insulin. In vitro studies, including the disease 
relapse assay, were based on protocols developed previously 
24
. Briefly, cells were plated at a 
density of 2 × 10
4
 cells/cm
2
 in the lower chamber of Transwells (Corning, New York, USA). 
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Cultures were allowed to recover for 24 h. Next, PEG-heparin hydrogel microparticle aggregates 
(100 µl) were added to the chamber inserts (0.4 µm pore size). As a control, free doxorubicin at 
doses of 4, 20, 40 and 80 µg was added to control wells to represent the total drug loading. For 
endpoint studies, cell viability was determined after a 72 h exposure time with (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) as a substrate. Following a 5 h 
incubation period, formazan was solubilized with dimethylsulfoxide, and the absorbance was 
measured at 560 nm.  
 
For long-term studies, analogous studies were performed using AlamarBlue (Invitrogen, Grand 
Island, NY, USA) instead of MTT and an initial seeding density of 1 × 10
4
 cells/cm
2
. At the 
indicated times, AlamarBlue was added to the culture medium, and cell viability was measured 
after a 4 h incubation period by monitoring fluorescence. Next, the medium was replaced with 
fresh culture medium, and cultures were continued. Disease relapse was mimicked by re-seeding 
the culture inserts at day 6 with 1 × 10
4
 cells/cm
2
, and viability was monitored as detailed above. 
The only culture that was not re-seeded was the control group because it had reached confluency 
by this time. 
 
Orthotopic human xenografts 
All in vivo studies were approved by the Institutional Animal Care and Use Committee (Protocol 
B2010-101), and animals were maintained under the guidelines established by the National 
Institute of Health and Tufts University. Tumour xenografts were induced using MDA-MB-231-
derived tumour cells that metastasized following orthotopic injection into mice; the tumours 
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carried the firefly luciferase gene to permit in vivo bioluminescence imaging 
25
. In vivo studies 
were based on protocols developed previously 
24
. Briefly, female NOD/SCID mice (NOD.CB17-
Prkdc
scid
/NcrCrl) aged 6 to 10 weeks were obtained from Charles River (Wilmington, MA, 
USA). A total of 5 × 10
5 
cells in 20 µl of Matrigel (BD Biosciences, Bedford, MA, USA) were 
injected bilaterally into the fat pad. Following tumour induction, mice (group sizes 4 to 5) were 
randomised and treated at day 12 with 100 µl of PEG-heparin hydrogel microparticle aggregates 
containing 40 µg doxorubicin; these injections were performed using a G26 needle. Mice 
received bilateral injections close to the tumour sites (i.e., 80 µg of doxorubicin/mouse) but were 
not given an intratumour injection. As a control, the equivalent doxorubicin dose of 80 µg was 
administered in 100 µl of PBS via a bolus tail vein injection to the control mice. Disease 
progression was monitored weekly by tumour cell-associated bioluminescence imaging using the 
Xenogen IVIS 200 imaging system controlled by the Living Image Software 4.2 (Caliper Life 
Sciences, Hopkinton USA). At the endpoint of the study, the brain, lung, liver and bones of each 
mouse were examined for metastasis, and the primary tumours were dissected and weighed. 
Histology was performed as detailed elsewhere 
24
. 
 
Statistical analysis 
Data were analysed using GraphPad Instat 5.0b (GraphPad Software, La Jolla USA). Sample 
pairs were analysed with the StudentÕs t-test. Multiple samples were evaluated by one-way 
analysis of variance followed by Bonferroni or DunnettÕs post hoc tests to evaluate the statistical 
differences (P ≤ 0.05) among all samples or between samples and controls, respectively. All 
error bars were standard deviation (SD) unless otherwise stated. An asterisk denotes statistical 
significance as follows: *P < 0.05, **P < 0.01, ***P < 0.001.  
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Results 
The heparin-modified PEG hydrogels synthesised with a 10 mg/ml heparin final concentration 
showed an average pore size of 6+/- 0.5 nm and 13 +/- 0.5 kPa stiffness 
21, 23
. Shearing was used 
to generate microparticles with an average mean diameter of 25-50 µm (Fig. 1a) and these 
microparticles were readily injectable through a G26 needle. Such particles form stable 
aggregates post injection and have defined viscoelastic properties; a storage modulus (i.e. 
stiffness) of 300 Pa and a loss modulus (i.e. viscous properties) of 90 Pa as reported previously 
by us
 23
.  These particles were loaded with doxorubicin (Fig. 1b); drug loading could be fine-
tuned over a broad  concentration range (4 to 80 µg doxorubicin/hydrogel) (Supplementary Fig. 
1). In vitro cumulative drug release studies showed complete doxorubicin release (> 95%) within 
100 hours for PEG-heparin hydrogel microparticle aggregates	with a 4 µg doxorubicin loading 
while 30% was achieved for 40 µg drug loaded carriers (Fig. 2a). Cumulative drug release 
studies revealed the relationship between doxorubicin release and drug loading. Following an 
initial transient burst release a zero-order like drug release rate was observed (Fig. 2c and d). 
These measurements were underpinned by equilibrium binding studies to assess the distribution 
of doxorubicin in the hydrogel and supernatant (Fig. 2b, Supplementary Fig. 2b, d, f); these 
measurements were used to calculate the binding and dissociation constants. The PEG-heparin 
hydrogel microparticle aggregates had an approximate doxorubicin binding constant of Ka 5 × 
10
2
 M
-1
 and a dissociation constant of Kb 2 × 10
-3
M
-1
.  
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Figure 1.  Schematic representation of the manufacture of drug-loaded microparticles. (A) 
Synthesis of heparin-modified polyethylene glycol (PEG) hydrogels; post synthesis hydrogels 
are processed into particles and drug loaded. (B) Images of control and doxorubicin-loaded PEG-
heparin hydrogel microparticle aggregates (HydroMicroAgg) in pre-filled 1 ml syringes for 
biological application and assessment. 
+ 
+ + 
SolGel formation PEG-heparin hydrogel Particle formation Doxorubicin loading
A
B
Pre-filled syringes with HydroMicroAgg 
Doxorubicin loaded Control 
Heparin starPEG Doxorubicin
25 - 50 µm
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Figure 2.  Drug release from PEG-heparin hydrogel microparticle aggregates (HydroMicroAgg). 
Cumulative doxorubicin release when buffer was (A) replaced with fresh one at each sampling 
time point or (B) kept throughout the experiment. Corresponding doxorubicin release rates when 
the release buffer was replaced (C) or (D) kept. Error bars are hidden in the plot-symbol when 
not visible, n=4; ±SD 
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The in vitro cytotoxicity of doxorubicin-loaded PEG-heparin hydrogel microparticle aggregates 
was assessed using human oestrogen-responsive breast cancer cells (MCF-7) and a highly 
aggressive triple negative breast cancer cell line (MDA-MB-231). Short-term (72h) cytotoxicity 
assays showed a significant antitumor response for MCF-7 cells (cell viability < 10%) across the 
tested concentration range, with a comparable response for freely diffusible drug and 
doxorubicin-loaded PEG-heparin hydrogel microparticle aggregates (Fig. 3a). In contrast, MDA-
MB-231 breast cancer cells showed approximately 30% cell viability at a 4 µg drug dose; this 
response was independent of the delivery mode (Fig. 3a). At all other drug concentrations, cell 
viability was < 10%, with no significant differences between freely diffusible drug and 
doxorubicin-loaded PEG-heparin hydrogel microparticle aggregates (Fig. 3a). We used a breast 
cancer relapse assay 
24
 to examine the full potential of doxorubicin-loaded PEG-heparin hydrogel 
microparticle aggregates (Fig. 3b). Freely diffusible doxorubicin and doxorubicin-loaded PEG-
heparin hydrogel microparticle aggregates showed significant cytotoxicity with no significant 
differences for the first 6 days of the assay (Fig. 3b). However, at day 8, the doxorubicin-loaded 
injectable PEG-heparin hydrogel microparticle aggregates continued to control breast cancer cell 
growth of both MCF-7 and MDA-MB-231 cell lines and significantly suppressed cell growth 
when compared to the diffusible doxorubicin control groups (Fig. 3b).  
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Figure 3. In vitro cytotoxicity of breast cancer cells treated with doxorubicin-loaded PEG-
heparin hydrogel microparticle aggregates (HydroMicroAgg). (A) Cell viability of MDA-MB-
231 and MCF7 cells treated for 72 h with HydroMicroAgg loaded with various amounts of 
doxorubicin and respective controls with equivalent amounts of diffusible doxorubicin. (B) 
Long-term cytotoxicity of free doxorubicin and HydroMicroAgg loaded with doxorubicin in 
MDA-MB-231 and MCF7 breast cancer cells. Culture medium was replaced at the indicated 
time. With the exception of the controls, all wells were re-seeded with the corresponding breast 
cancer cells at day 6. Significant differences between diffusible doxorubicin and the other 
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doxorubicin treatment groups were determined, followed by DunnettÕs multiple comparison post 
hoc test, ***P < 0.0001; error bars are hidden in the plot-symbol when not visible, ±SD; n = 4. 
 
Based on these in vitro study results, we assessed the ability of doxorubicin-loaded PEG-heparin 
hydrogel microparticle aggregates to control tumour growth in vivo (Fig. 4a). Because triple 
negative breast cancer poses a real clinical challenge, we tested our delivery system using triple 
negative MDA-MB-231 orthotopic breast cancer model. Bioluminescence monitoring of animals 
treated with drug-loaded PEG-heparin hydrogel microparticle aggregates revealed a significantly 
reduced tumour burden at 3 weeks and all subsequent time points when compared to bolus-
treated mice (Fig. 4b). Dissection and weighing of tumours from animals treated with drug-
loaded PEG-heparin hydrogel microparticle aggregates confirmed a significantly reduced tumour 
burden when compared to bolus-treated animals (Fig. 4 b). Assessment for breast cancer 
metastasis revealed that animals treated with drug-loaded PEG-heparin hydrogel microparticle 
aggregates showed a small increase in lung metastasis, whereas metastasis to brain, liver and 
bone showed a substantial reduction when compared to the bolus-treated animals (Fig. 4 c).  
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Figure 4. In vivo response of doxorubicin-loaded PEG-heparin hydrogel microparticle 
aggregates (HydroMicroAgg). (A) Schematic of the experimental approach. (B) Treatment of 
tumour-bearing mice either with doxorubicin-loaded HydroMicroAgg or the equivalent amount 
of doxorubicin administered by intravenous bolus dosing. Tumour growth was monitored in vivo 
by non-invasive, cancer cell-specific bioluminescence imaging and primary tumour weights were 
assessed the end of the study. (C) Bioluminescence images of mice at week 6 and metastatic 
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spread of cancer cells to organs at week 6. Statistical differences were determined using unpaired 
T-test, **P<0.005, ***P<0.001; ± SD tumour weights and standard error of the mean for tumour 
growth; error bars are hidden in the plot-symbol when not visible, n=5 doxorubicin i.v., n=4 
PEG-heparin hydrogel microparticle aggregates.  
 
PEG-heparin hydrogel microparticle aggregates remained within the initial injection site and did 
not dislocate over the course of the study. PEG-heparin hydrogel microparticle aggregate 
samples retrieved and subjected to histological examination (Fig. 5) were readily identifiable 
(Fig. 5 a) and discrete hydrogel microparticles were visible in histological sections (Fig. 5 c). 
Overall, PEG-heparin hydrogel microparticle aggregates showed a low foreign body response, 
with minimal cell infiltration and connective tissue encapsulation at both the ventral and dorsal 
orientation (Fig. 5a-c).  
 
		
19	
 
Figure 5. In vivo histocompatibility assessment of PEG-heparin hydrogel microparticle 
aggregates (HydroMicroAgg). Histological section and H&E staining of HydroMicroAgg; 
samples were retrieved from the study detailed in Figure 4. (A) Low magnification image 
showing HydroMicroAgg (scale bar 1,000 µm). Higher magnifications for areas 1 and 2 are 
shown in panel (B) and (C), respectively (all scale bars 250 µm). Dotted lines in panel (C) 
delineate particle outlines. 
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Discussion  
Our aim was to assess heparin-containing polyethylene glycol microparticle aggregates for focal 
cancer chemotherapy. We selected PEG and heparin as building blocks of our formulation 
because of the substantial clinical experience with both materials. For example, PEG is a 
commonly used excipient in pharmaceutical preparations (e.g., Molaxole¨, Movicol¨) where 
several grams of PEG (MW between 3.000 Ð 6.000 g/mol) are administered orally. Furthermore, 
PEG is commonly used to modulate the pharmacokinetics of nanomedicines by grafting the 
polymer to proteins, peptides, aptamers or small molecular weight drugs (reviewed in 
26-27
). 
Typically PEG is regarded as a ÒsafeÓ polymer for a broad spectrum of applications; this is 
achieved by controlling both the MW and dose.  
 
For hydrogel-based systems intended for subcutaneous administration, PEG induces a minimal 
foreign body response because it limits nonspecific protein adsorption on the implant surface 
28
. 
Protein adsorption, also known as fouling, is considered to be the first step in the foreign body 
response 
29
. Any implanted material will induce a foreign body response, but PEG-based systems 
show very low fouling properties 
28, 30
. This clinical track record for PEG prompted its selection 
in the present study for the generation of hydrogel microparticles for controlled drug delivery. 
We wanted to endow these PEG hydrogel with improved drug release capabilities, so we 
generated heparin-functionalised hydrogels (Fig. 1) by crosslinking the carboxylic acid groups of 
heparin with the four primary amine groups of starPEG using carbodiimide chemistry (Fig. 1a) 
22
. The starPEG-heparin hydrogel reported here is stable towards cell-mediated enzymatic 
degradation 
31
. Furthermore, these hydrogels have shown remarkable non-cell-adhesive 
properties that are comparable to fully synthetic PEG hydrogels 
32
. Heparin is particularly well 
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suited for the intended application because it has known anticancer activity in its unbound form 
(i.e. freely diffusible) 
17
. Notably, the anticancer activity of heparin conjugated into material has 
not been described previously, to the best of our knowledge. Our other intention was to explore 
the possibility that the negative net charge of heparin could facilitate the binding of drugs like 
doxorubicin, a weakly basic anticancer drug. The physical properties of these PEG-heparin 
hydrogel-based microparticle aggregates, characterised previously using dynamic mechanical 
analysis 
23
, confirmed that injectable hydrogel aggregates behave as intact hydrogel after 
injection.   
 
Drug release from PEG-heparin hydrogel microparticle aggregates	 was dependent on drug 
loading (Fig. 2, Supplementary Fig. 2). Here, complete drug release was achieved for systems 
loaded with 4 µg of doxorubicin while 30% drug release was achieved for 40 µg drug loaded 
PEG-heparin hydrogel microparticle aggregates. These data suggest that doxorubicin release was 
not following a linear, dose dependent release profile. One possible explanation is doxorubicinÕs 
ability to π-π stack that becomes more prominent at higher drug loadings. Calculations of 
binding and a dissociation constants suggested a complex doxorubicin release mechanism with a 
significant contribution of the hydrogel on doxorubicin diffusion and release kinetics because the 
calculated dissociation constant was too high to sustain the experimentally observed long-term 
drug release kinetics. Next, we examined the in vitro response of our doxorubicin-loaded PEG-
heparin microparticle aggregates using the oestrogen receptor-positive, hormone-responsive, 
Her2/neu-negative breast cancer cell line (MCF7) and triple negative breast cancer cells (MDA-
MB-231) (Fig. 3). All treatment groups showed an excellent response in short-term cytotoxicity 
assays. However, our breast cancer relapse assay showed that the diffusible doxorubicin 
-	 22	
treatment failed to control outgrowth of breast cancer cells (Fig. 3b). In contrast, our drug-loaded 
PEG-heparin hydrogel microparticle aggregates controlled breast cancer cell growth over the 
entire study period. These results strongly suggest that, under these in vitro culture conditions, 
doxorubicin was released at cytotoxic concentrations over an extended period of time. We have 
previously used this short term cytotoxicity assay and the relapse assay to assess silk hydrogels 
33
 
and films 
24
 for their ability to release cytotoxic drugs and precision medicines 
13-14
. In all these 
previous studies, we obtained a similar therapeutic response to that detailed here (Fig. 3).  
 
Our previous excellent translation of in vitro results into orthotopic neuroblastoma and breast 
cancer in vivo models 
13-14, 24
 prompted us to assess the therapeutic potential of doxorubicin-
loaded PEG-heparin microparticle aggregates in orthotopic MDA-MB-231 breast cancers. Local 
injection of doxorubicin-loaded PEG-heparin microparticle aggregates, once breast tumours were 
established, revealed that focal doxorubicin delivery significantly reduced tumour growth from 3 
weeks until the end of the study when compared to the bolus control treatment (Fig. 4b). We also 
observed significantly smaller primary tumours and reduced metastasis for animals that were 
treated with doxorubicin-loaded PEG-heparin hydrogel microparticle aggregates. However, none 
of the animals showed complete tumour regression, which was previously observed for 
doxorubicin-loaded silk hydrogels in 2 out of 5 animals 
33
. Furthermore, the primary tumour 
sizes in the current study and in the silk hydrogel study were 345 mg and 142 mg, respectively, 
although the tumour model, doxorubicin dose and dosing schedule were identical in both studies. 
The in vitro doxorubicin release from PEG-heparin hydrogel microparticle aggregates showed a 
substantially faster drug release profile when compared to silk hydrogels 
33
. This is likely to have 
direct consequences in vivo. Therefore, additional refinements of anticancer drug release from 
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PEG-heparin hydrogel microparticle aggregates is likely to result in further enhancement of the 
antitumour response. 
 
Histological examination showed a good in vivo tissue compatibility of PEG-heparin hydrogel 
microparticle aggregates, which was coupled with the ability of these hydrogels to retain their 
shape at the injection site. This observation is in line with previous observations that PEG based 
hydrogels are particularly well suited for in vivo applications 
28
. For example, previous in vivo 
studies with PEG-heparin hydrogels showed that application of these hydrogels into the striatum 
of rats induced a low transient presence of microglia and a mild astroglial reaction at the 
hydrogelÐbrain interface at one week after implantation 
22
. Over the 21 day study period, a good 
histocompatibility was observed, with no significant adverse tissue responses 
22
.  
 
Conclusions 
This study demonstrates that heparin-modified PEG hydrogel microparticle aggregates are well 
placed for the focal delivery of anticancer drugs. Doxorubicin-loaded hydrogel microparticle 
aggregates showed an excellent in vitro response and a significant antitumour effect in an 
aggressive orthotopic breast cancer model. Drug-loaded PEG-heparin hydrogel microparticle 
aggregates induced a reduction in both primary tumour growth and metastasis, while histological 
assessment at the end of the study showed good histocompatibility. Overall, these findings, when 
combined with prior in vivo data on PEG-heparin hydrogels, support a viable future for PEG-
heparin hydrogel microparticle aggregates in (anticancer) drug delivery applications.  
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Supplementary Figure 1 Representative images of PEG-heparin hydrogel microparticle 
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Supplementary Figure 2. Drug release from PEG-heparin hydrogel microparticle aggregates 
(HydroMicroAgg).  
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Supplementary Figure 1 Representative images of PEG-heparin hydrogel microparticle 
aggregates loaded with different amounts of doxorubicin. Dashed line indicates the interface 
between the hydrogel (arrow) and PBS; scale bare 15 mm. 
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Supplementary Figure 2. Drug release from PEG-heparin hydrogel microparticle aggregates 
(HydroMicroAgg). Cumulative doxorubicin release when buffer was (A) replaced with fresh one 
at each sampling time point or (B) kept throughout the experiment. Corresponding doxorubicin 
release relative to initial loading. Doxorubicin release rates when the release buffer was replaced 
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(E) or (F) kept. Note that release was from 50 µl HydroMicroAgg samples; nominal doxorubicin 
loadings of 4 Ð 80 µg correspond to 100 µl of sample 
 
